Irene Vourliotaki, Ingrid Elizabeth Bonapart, Catherine Stamataki, Eva-Maria Tsapakis, Catherine Saridaki
Dopamine agonists are the drugs of choice in the treatment of prolactinomas, the most common type of pituitary adenomas. However, up to 25% of prolactinomas do not respond to these drugs and alternative treatments have to be considered. We describe a 37-year old female with a microprolactinoma who, although having received all available formulations of dopamine agonists …